Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Semiglazov Vf et al.|Annals of Oncology|2021Cited by 724
MDM2 Promotes Invasion and Metastasis in Invasive Ductal Breast Carcinoma by Inducing Matrix Metalloproteinase-9Xiaofeng Chen, Yongmei Yin|PLoS ONE|2013Cited by 47
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Tao Sun et al.|Journal of Clinical Oncology|2022Cited by 36
SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancersJie Mei, Yongmei Yin|iScience|2023Cited by 21
Overcoming ABCB1-mediated multidrug resistance by transcription factor BHLHE40Yongmei Yin, Jing Xiong, Xin Yu et al.|Neoplasia|2023Cited by 8